LRMR – larimar therapeutics, inc. (US:NASDAQ)

News

Larimar Therapeutics (LRMR) had its price target raised by Wedbush from $12.00 to $13.00. They now have an "outperform" rating on the stock.
Larimar Therapeutics GAAP EPS of -$0.73 misses by $0.22 [Seeking Alpha]
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Larimar Therapeutics price target raised to $12 from $11 at Wedbush [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com